Curaleaf Holdings (CURLF) Liabilities and Shareholders Equity (2019 - 2025)

Curaleaf Holdings (CURLF) posted quarterly Liabilities and Shareholders Equity of $2.8 billion for Q4 2025, down 3.54% year-on-year from $2.9 billion in Q4 2024, and down 3.54% on a QoQ basis from $2.9 billion in Q4 2024.

Curaleaf Holdings (CURLF) Liabilities and Shareholders Equity (2019 - 2025) Analysis & Trends

Curaleaf Holdings (CURLF) has reported Liabilities and Shareholders Equity for 7 consecutive years, with $2.8 billion the latest figure, recorded in Q4 2025.

  • Quarterly Liabilities and Shareholders Equity fell 3.54% year-over-year to $2.8 billion in Q4 2025, while the trailing twelve-month figure through Mar 2026 was $2.8 billion (down 68.76% YoY) and the FY2025 annual result came in at $2.8 billion, down 3.54% from the prior year.
  • Liabilities and Shareholders Equity slipped to $2.8 billion in Q4 2025 per CURLF's latest filing, from $2.9 billion in the prior quarter.
  • Over the last five years, Liabilities and Shareholders Equity for CURLF reached as high as $3.5 billion in Q1 2022 and fell as low as $737.0 million in Q4 2021.
  • A 5-year average of $2.9 billion and a median of $3.1 billion in 2023 frame the typical range for Liabilities and Shareholders Equity.
  • Annual changes were most pronounced in 2021 — Liabilities and Shareholders Equity sank 68.84% — and 2022, when it jumped 363.29%.
  • Year by year, Liabilities and Shareholders Equity stood at $737.0 million in 2021, then surged by 363.29% to $3.4 billion in 2022, then dropped by 9.31% to $3.1 billion in 2023, then dropped by 4.74% to $2.9 billion in 2024, then fell by 3.54% to $2.8 billion in 2025.
  • According to Business Quant data, Liabilities and Shareholders Equity over the past three periods registered $2.8 billion, $2.9 billion, and $3.1 billion for Q4 2025, Q4 2024, and Q3 2024 respectively.

Peer Comparison

# Company Market Cap Enterprise Value Gross Profit (Qtr) Liabilities and Shareholders Equity (Qtr)
1 Haleon 87.22 Bn 85.35 Bn - 43.40 Bn
2 Teva Pharmaceutical Industries 39.60 Bn 35.87 Bn 1.97 Bn 40.04 Bn
3 Zoetis 31.46 Bn 29.52 Bn 1.62 Bn 15.15 Bn
4 Takeda Pharmaceutical 26.49 Bn 22.44 Bn 4.39 Bn 98.91 Bn
5 United Therapeutics 23.03 Bn 20.88 Bn 648.10 Mn 6.71 Bn
6 Universe Pharmaceuticals 23.03 Bn -10.56 Bn - 69.30 Bn
7 Viatris 20.90 Bn 19.09 Bn 1.16 Bn 36.83 Bn
8 Neurocrine Biosciences 17.50 Bn 16.19 Bn 800.70 Mn 4.91 Bn
9 Elanco Animal Health 12.33 Bn 11.91 Bn 785.00 Mn 13.22 Bn
10 Curaleaf Holdings 7.13 Bn 7.13 Bn 157.29 Mn -

Historic Data

Download Data
DateValue
Dec 31, 2025 2.85 Bn
Dec 31, 2024 2.95 Bn
Sep 30, 2024 3.07 Bn
Jun 30, 2024 3.08 Bn
Dec 31, 2023 3.10 Bn
Sep 30, 2023 3.23 Bn
Jun 30, 2023 3.30 Bn
Dec 31, 2022 3.41 Bn
Mar 31, 2022 3.55 Bn
Dec 31, 2021 737.03 Mn
Sep 30, 2021 3.17 Bn
Jun 30, 2021 3.15 Bn
Mar 31, 2021 2.68 Bn
Dec 31, 2020 2.37 Bn
Sep 30, 2020 2.36 Bn
Dec 31, 2019 736.93 Mn